<a href="https://laohu8.com/S/CYTK">Cytokinetics</a> Reports Q3 Revenue of $1.9 Million
Cytokinetics reported total revenues of $1.9 million for the third quarter of 2025, up from $0.5 million in the same period in 2024. Research and development expenses were $99.2 million, including $15.1 million in non-cash stock-based compensation, compared to $84.6 million in the prior year period. General and administrative expenses rose to $69.5 million, including $15.6 million in non-cash stock-based compensation, from $56.7 million in the third quarter of 2024. The company reported a net loss of $306.2 million, or $(2.55) per share, compared to a net loss of $160.5 million, or $(1.36) per share, for the same quarter last year. The net loss includes a debt conversion expense of $121.2 million related to the induced exchange of the 2027 Notes. As of September 30, 2025, Cytokinetics had approximately $1.25 billion in cash, cash equivalents, and investments. Key business developments include progress toward the December 26, 2025 PDUFA date for aficamten, ongoing regulatory reviews in China and the European Union, and continued commercial launch preparations in the U.S.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569673-en) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.